바이오인포매틱스 서비스 시장 - 규모, 점유율, 성장률, 산업 분석 : 유형별, 용도별, 지역별 인사이트 및 예측(2026-2034년)

Growth Factors of bioinformatics services Market

The global bioinformatics services market was valued at USD 6.51 billion in 2025 and is projected to grow from USD 7.82 billion in 2026 to USD 22.03 billion by 2034, registering a robust CAGR of 13.83% during the forecast period. North America dominated the market with a share of 45.87% in 2025, supported by strong research infrastructure, large-scale genomic initiatives, and the presence of major service providers.

Bioinformatics is an interdisciplinary field integrating computer science, biostatistics, and life sciences to analyze and interpret vast volumes of biological data. Bioinformatics services play a crucial role in genomic and proteomic biomarker discovery, drug development, disease diagnosis, and personalized medicine. The expanding application of these services across healthcare, agriculture, forensic science, veterinary science, and biotechnology is accelerating global market penetration.

Market Drivers

One of the primary growth drivers is the rising adoption of cloud-based bioinformatics solutions, which reduce operational costs and improve accessibility to large clinical datasets. Governments and healthcare organizations are increasingly focusing on implementing these solutions to accelerate research workflows and meet the growing demand for personalized medicine.

The increasing outsourcing of bioinformatics services by pharmaceutical and biotechnology companies to analyze clinical trial and drug discovery data has further boosted market growth. Rapid innovation in genomics, proteomics, and biopharmaceutical research is driving demand for advanced data interpretation services.

During the COVID-19 pandemic, the bioinformatics services market experienced positive growth due to the urgent need to analyze viral genomic data. Increased investments by governments and industry players to support vaccine and therapeutic development significantly contributed to revenue growth during this period.

Market Trends

A key trend shaping the market is the growing application of bioinformatics in personalized medicine and vaccine development. Advanced sequencing technologies and analytical tools enable precise diagnosis, targeted therapies, and improved treatment outcomes with reduced side effects.

Bioinformatics is increasingly used in gene sequencing diagnostics, disease risk prediction, drug discovery, and personalized vaccination strategies. The integration of artificial intelligence and machine learning into genomic data analysis is further enhancing research efficiency while reducing time and cost associated with clinical studies.

Restraining Factors

Despite strong growth prospects, the market faces challenges related to data management, standardization, and ethical concerns. Managing diverse and complex biological datasets requires skilled professionals, which are in limited supply in emerging regions.

Ethical and legal issues related to genomic data storage, sharing, and privacy remain unresolved in many countries. Additionally, the lack of standardized guidelines for handling large-scale biological datasets and the need for continuous upgrades in sequencing and data storage infrastructure may restrict market growth to some extent.

Segmentation Analysis

By Service Type:

The sequencing segment dominated the market with a share of 37.72% in 2026, driven by the widespread adoption of next-generation sequencing technologies and declining sequencing costs. Data analysis and drug discovery services also held substantial market shares due to their critical role in genomics and pharmaceutical research.

By Application:

The genomics segment accounted for 35.68% of the global market share in 2026, supported by increasing genomic research programs and government funding. Metabolomics and pharmacology also contributed significantly, while transcriptomics offers emerging growth opportunities.

By End User:

The pharmaceutical and biotechnology companies segment dominated with a 45.52% share in 2026, driven by extensive clinical research activities and the integration of bioinformatics to accelerate drug discovery. CROs and research institutes also held a significant share due to cost and time efficiency.

Regional Insights

• North America: Generated USD 2.99 billion in 2025, supported by strong government investments and a well-established bioinformatics infrastructure.
• Europe: Witnessed steady growth due to increasing genomics funding and personalized medicine initiatives.
• Asia Pacific: Expected to grow at the highest CAGR, driven by rising clinical trial activity. By 2026, Japan is projected to reach USD 0.75 billion, China USD 0.43 billion, and India USD 0.33 billion.
• Latin America & Middle East & Africa: Moderate growth due to limited infrastructure and lower adoption rates.

Competitive Landscape

Key players include Illumina, QIAGEN, Thermo Fisher Scientific, Eurofins Scientific, CD Genomics, and Excelra. These companies focus on strategic collaborations, acquisitions, and technological advancements to expand their service offerings and global presence.

Conclusion

The global bioinformatics services market is poised for significant growth from 2025 to 2034, driven by rising demand for genomic data analysis, personalized medicine, and drug discovery services. While challenges related to data management and ethical concerns persist, continuous technological advancements, strong government support, and expanding applications across healthcare and life sciences are expected to sustain market momentum. By 2034, the market is projected to reach USD 22.03 billion, reflecting the growing importance of bioinformatics services in modern biomedical research and healthcare innovation.

Segmentation By Service Type

• Sequencing
• Gene Expression
• Data Analysis
• Drug Discovery
• Others

By Application

• Metabolomics
• Pharmacology
• Genomics
• Transcriptomics
• Others

By End User

• Pharmaceutical & Biotechnological Companies
• CROs & Research Institutes
• Others

By Region

• North America (By Service Type, Application, End-User, By Country)
  • U.S.
  • Canada
• Europe (By Service Type, Application, End-User, Country/Sub-Region)
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific (By Service Type, Application, End-User, Country/Sub-Region)
  • Japan
  • China
  • India
  • Australia
  • Rest of Asia Pacific
• Latin America (By Service Type, Application, End-User, Country/Sub-Region)
  • Brazil
  • Mexico
  • Rest of Latin America
• Middle East & Africa (By Service Type, Application, End-User, Country/Sub-Region)
  • GCC
  • South Africa
  • Rest of the Middle East & Africa

Table of Content

1. Introduction

• 1.1. Research Scope
• 1.2. Market Segmentation
• 1.3. Research Methodology
• 1.4. Definitions and Assumptions

2. Executive Summary

3. Market Dynamics

• 3.1. Market Drivers
• 3.2. Market Restraints
• 3.3. Market Opportunities
• 3.4. Market Trends

4. Key Insights

• 4.1. Key Industry Developments - Mergers, Acquisitions & Partnerships
• 4.2. Technological Advancement in Bioinformatics
• 4.3. Impact of COVID-19 on the Market

5. Global Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 5.1. Market Analysis, Insights and Forecast - By Service Type
  • 5.1.1. Sequencing
  • 5.1.2. Gene Expression
  • 5.1.3. Data Analysis
  • 5.1.4. Drug Discovery
  • 5.1.5. Others
• 5.2. Market Analysis, Insights and Forecast - By Application
  • 5.2.1. Metabolomics
  • 5.2.2. Pharmacology
  • 5.2.3. Genomics
  • 5.2.4. Transcriptomics
  • 5.2.5. Others
• 5.3. Market Analysis, Insights and Forecast - By End User
  • 5.3.1. Pharmaceutical & Biotechnological Companies
  • 5.3.2. CROs & Research Institutes
  • 5.3.3. Others
• 5.4. Market Analysis, Insights and Forecast - By Region
  • 5.4.1. North America
  • 5.4.2. Europe
  • 5.4.3. Asia Pacific
  • 5.4.4. Latin America
  • 5.4.5. Middle East & Africa

6. North America Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 6.1. Market Analysis, Insights and Forecast - By Service Type
  • 6.1.1. Sequencing
  • 6.1.2. Gene Expression
  • 6.1.3. Data Analysis
  • 6.1.4. Drug Discovery
  • 6.1.5. Others
• 6.2. Market Analysis, Insights and Forecast - By Application
  • 6.2.1. Metabolomics
  • 6.2.2. Pharmacology
  • 6.2.3. Genomics
  • 6.2.4. Transcriptomics
  • 6.2.5. Others
• 6.3. Market Analysis, Insights and Forecast - By End User
  • 6.3.1. Pharmaceutical & Biotechnological Companies
  • 6.3.2. CROs & Research Institutes
  • 6.3.3. Others
• 6.4. Market Analysis, Insights and Forecast - By Country
  • 6.4.1. U.S.
  • 6.4.2. Canada

7. Europe Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 7.1. Market Analysis, Insights and Forecast - By Service Type
  • 7.1.1. Sequencing
  • 7.1.2. Gene Expression
  • 7.1.3. Data Analysis
  • 7.1.4. Drug Discovery
  • 7.1.5. Others
• 7.2. Market Analysis, Insights and Forecast - By Application
  • 7.2.1. Metabolomics
  • 7.2.2. Pharmacology
  • 7.2.3. Genomics
  • 7.2.4. Transcriptomics
  • 7.2.5. Others
• 7.3. Market Analysis, Insights and Forecast - By End User
  • 7.3.1. Pharmaceutical & Biotechnological Companies
  • 7.3.2. CROs & Research Institutes
  • 7.3.3. Others
• 7.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 7.4.1. U.K.
  • 7.4.2. Germany
  • 7.4.3. France
  • 7.4.4. Spain
  • 7.4.5. Italy
  • 7.4.6. Rest of Europe

8. Asia Pacific Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 8.1. Market Analysis, Insights and Forecast - By Service Type
  • 8.1.1. Sequencing
  • 8.1.2. Gene Expression
  • 8.1.3. Data Analysis
  • 8.1.4. Drug Discovery
  • 8.1.5. Others
• 8.2. Market Analysis, Insights and Forecast - By Application
  • 8.2.1. Metabolomics
  • 8.2.2. Pharmacology
  • 8.2.3. Genomics
  • 8.2.4. Transcriptomics
  • 8.2.5. Others
• 8.3. Market Analysis, Insights and Forecast - By End User
  • 8.3.1. Pharmaceutical & Biotechnological Companies
  • 8.3.2. CROs & Research Institutes
  • 8.3.3. Others
• 8.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 8.4.1. Japan
  • 8.4.2. China
  • 8.4.3. India
  • 8.4.4. Australia
  • 8.4.5. Rest of Asia Pacific

9. Latin America Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 9.1. Market Analysis, Insights and Forecast - By Service Type
  • 9.1.1. Sequencing
  • 9.1.2. Gene Expression
  • 9.1.3. Data Analysis
  • 9.1.4. Drug Discovery
  • 9.1.5. Others
• 9.2. Market Analysis, Insights and Forecast - By Application
  • 9.2.1. Metabolomics
  • 9.2.2. Pharmacology
  • 9.2.3. Genomics
  • 9.2.4. Transcriptomics
  • 9.2.5. Others
• 9.3. Market Analysis, Insights and Forecast - By End User
  • 9.3.1. Pharmaceutical & Biotechnological Companies
  • 9.3.2. CROs & Research Institutes
  • 9.3.3. Others
• 9.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 9.4.1. Brazil
  • 9.4.2. Mexico
  • 9.4.3. Rest of Latin America

10. Middle East & Africa Bioinformatics Services Market Analysis, Insights and Forecast, 2021-2034

• 10.1. Market Analysis, Insights and Forecast - By Service Type
  • 10.1.1. Sequencing
  • 10.1.2. Gene Expression
  • 10.1.3. Data Analysis
  • 10.1.4. Drug Discovery
  • 10.1.5. Others
• 10.2. Market Analysis, Insights and Forecast - By Application
  • 10.2.1. Metabolomics
  • 10.2.2. Pharmacology
  • 10.2.3. Genomics
  • 10.2.4. Transcriptomics
  • 10.2.5. Others
• 10.3. Market Analysis, Insights and Forecast - By End User
  • 10.3.1. Pharmaceutical & Biotechnological Companies
  • 10.3.2. CROs & Research Institutes
  • 10.3.3. Others
• 10.4. Market Analysis, Insights and Forecast - By Country/ Sub-Region
  • 10.4.1. GCC
  • 10.4.2. South Africa
  • 10.4.3. Rest of Middle East & Africa

11. Competitive Analysis

• 11.1. Global Market Share Analysis (2025)
• 11.2. Company Profiles
  • 11.2.1. Illumina, Inc.
    • 11.2.1.1. Overview
    • 11.2.1.2. Products & Services
    • 11.2.1.3. SWOT Analysis
    • 11.2.1.4. Recent Developments
    • 11.2.1.5. Strategies
    • 11.2.1.6. Financials (Based on Availability)
  • 11.2.2. QIAGEN
    • 11.2.2.1. Overview
    • 11.2.2.2. Products & Services
    • 11.2.2.3. SWOT Analysis
    • 11.2.2.4. Recent Developments
    • 11.2.2.5. Strategies
    • 11.2.2.6. Financials (Based on Availability)
  • 11.2.3. CD Genomics
    • 11.2.3.1. Overview
    • 11.2.3.2. Products & Services
    • 11.2.3.3. SWOT Analysis
    • 11.2.3.4. Recent Developments
    • 11.2.3.5. Strategies
    • 11.2.3.6. Financials (Based on Availability)
  • 11.2.4. Excelra
    • 11.2.4.1. Overview
    • 11.2.4.2. Products & Services
    • 11.2.4.3. SWOT Analysis
    • 11.2.4.4. Recent Developments
    • 11.2.4.5. Strategies
    • 11.2.4.6. Financials (Based on Availability)
  • 11.2.5. Creative Proteomics
    • 11.2.5.1. Overview
    • 11.2.5.2. Products & Services
    • 11.2.5.3. SWOT Analysis
    • 11.2.5.4. Recent Developments
    • 11.2.5.5. Strategies
    • 11.2.5.6. Financials (Based on Availability)
  • 11.2.6. Fios Genomics.
    • 11.2.6.1. Overview
    • 11.2.6.2. Products & Services
    • 11.2.6.3. SWOT Analysis
    • 11.2.6.4. Recent Developments
    • 11.2.6.5. Strategies
    • 11.2.6.6. Financials (Based on Availability)
  • 11.2.7. Thermo Fisher Scientific Inc.
    • 11.2.7.1. Overview
    • 11.2.7.2. Products & Services
    • 11.2.7.3. SWOT Analysis
    • 11.2.7.4. Recent Developments
    • 11.2.7.5. Strategies
    • 11.2.7.6. Financials (Based on Availability)
  • 11.2.8. Eurofins Scientific
    • 11.2.8.1. Overview
    • 11.2.8.2. Products & Services
    • 11.2.8.3. SWOT Analysis
    • 11.2.8.4. Recent Developments
    • 11.2.8.5. Strategies
    • 11.2.8.6. Financials (Based on Availability)
  • 11.2.9. Psomagen
    • 11.2.9.1. Overview
    • 11.2.9.2. Products & Services
    • 11.2.9.3. SWOT Analysis
    • 11.2.9.4. Recent Developments
    • 11.2.9.5. Strategies
    • 11.2.9.6. Financials (Based on Availability)